- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01260506
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
April 23, 2020 updated by: Vascular Biogenics Ltd. operating as VBL Therapeutics
The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
75
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tel Aviv, Israel, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States
- Dana Farber Cancer Institute
-
-
North Carolina
-
Durham, North Carolina, United States
- Duke University Medical Center
-
-
Texas
-
San Antonio, Texas, United States
- Uthsc- Ctrc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects must have a histologically confirmed diagnosis of glioblastoma multiforme or gliosarcoma;
- Measurable disease by RANO criteria;
- Disease progression or recurrence following standard of care treatment with temozolomide and radiation;
- An interval of at least 4 weeks between prior surgical resection and study enrollment;
- An interval of at least 12 weeks between prior radiotherapy or at least 4 weeks from prior chemotherapy, and enrollment in this protocol;
- Recovered to Grade 1 or less from the toxic effects of any earlier intervention;
- Karnofsky performance status > 60%
Exclusion Criteria:
- Prior anti-angiogenic therapy including VEGF sequestering agents (ie bevacizumab, aflibercept, etc) or VEGFR inhibitors (cediranib, pazopanib, sunitinib, sorafenib, etc);
- Prior stereotactic radiotherapy;
- Active infection;
- Evidence of CNS haemorrhage CTCAE grade 2 or above on baseline MRI;
- Subjects who suffered from an acute cardiac event within the last 12 months;
- Subjects with active vascular disease, either myocardial or peripheral;
- Subjects with proliferative and/or vascular retinopathy;
- Subjects with known active second malignancy;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VB-111
Antiangiogenic and vascular disruptive agent
|
Upon progression, subjects will receive a combination therapy of VB-111 and standard of care bevacizumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival
Time Frame: From date of study entry until the date of death from any cause (up to 10 years)
|
From date of study entry until the date of death from any cause (up to 10 years)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression Free Survival
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2010
Primary Completion (Actual)
July 23, 2015
Study Completion (Actual)
December 20, 2018
Study Registration Dates
First Submitted
December 13, 2010
First Submitted That Met QC Criteria
December 14, 2010
First Posted (Estimate)
December 15, 2010
Study Record Updates
Last Update Posted (Actual)
April 24, 2020
Last Update Submitted That Met QC Criteria
April 23, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- VB-111-122
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma Multiforme
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
University of UtahWithdrawnGlioblastoma Multiforme (GBM)United States
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Sunnybrook Health Sciences CentreRecruitingGlioblastoma Multiforme, AdultCanada
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingGlioblastoma Multiforme, AdultChina
-
Polaris GroupRecruitingGlioblastoma Multiforme (GBM)Taiwan
-
University of IowaEisai Inc.TerminatedPrimary Glioblastoma MultiformeUnited States
Clinical Trials on VB-111
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsUnknownAdvanced and/or Metastatic Solid Organ CancerUnited States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedDifferential Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedMetastatic Colorectal Cancer | Colorectal Neoplasms | Colorectal Tumors | Colorectal Carcinoma | Colorectal Cancer With Hepatic MetastasesUnited States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedPsoriasisGermany, Israel, Poland, Spain
-
Vyome Therapeutics Inc.UnknownAcne VulgarisUnited States
-
Hospital de Clinicas de Porto AlegreCompletedPhysical Disability | Mucociliary Clearance Defect
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedGlioblastomaUnited States, Israel, Canada
-
ViscofanMinisterio de Ciencia e Innovación, SpainUnknownHeart Failure With Reduced Ejection FractionSpain
-
Priscilla Hsue, MDUniversity of California, Los Angeles; University of UtahWithdrawnHIV Infection | Inflammation | Cardiovascular DiseaseUnited States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedActive Plaque PsoriasisUnited States, Germany, Israel